On Thursday, Shares of King Digital Entertainment PLC (NYSE:KING), lost -5.42% to $15.00.
Discover a new island and a new way of life! King Digital Entertainment plc (KING), a leading interactive entertainment company for the mobile world and the creator of the Candy Crush franchise, will transport players to a tropical island paradise as it launches its first simulation game, Paradise Bay. Accessible to download for free on iOS recently and coming to Android soon, players will embark on an exciting journey of exploration and discovery as they build and customize their very own tropical paradise and return the island to its earlier days of flourishing prosperity and booming business.
Paradise Bay starts as players arrive on the island in a quest to transform their new home into a thriving port and market. They will journey through lands of crystal clear waters and the bluest of skies, collecting long-lost map pieces and selling their wares to players from around the world. They will also discover exciting new islands where they can find great deals, unique gifts and surprises and trade with the characters they meet. New trade routes will open up and new relationships will blossom, creating a world of endless discovery and possibility.
King Digital Entertainment plc, an interactive entertainment company, produces and distributes digital games on multiple platforms in the United States, the United Kingdom, Germany, and internationally.
Shares of Goodrich Petroleum Corporation (NYSE:GDP), inclined 0.54% to $0.750, during its last trading session.
Goodrich Petroleum Corporation declared the Company’s administration team will present at EnerCom’s The Oil & Gas Conference 20 at the Westin Downtown Denver Hotel located at 1672 Lawrence Street in Denver, Colorado on Monday, August 17, 2015 at 2:20 PM MT.
Goodrich Petroleum Corporation, an independent oil and natural gas company, engages in the exploration, development, and production of oil and natural gas. The company holds interest in the Tuscaloosa Marine Shale located in southwest Mississippi and southeast Louisiana; the Eagle Ford Shale Trend located in South Texas; and the Haynesville Shale Trend in Northwest Louisiana and East Texas.
At the end of Thursday’s trade, Shares of Tripadvisor Inc (NASDAQ:TRIP), lost -2.36% to $76.12.
Brewster Travel Canada, declared that its Glacier Adventure experience at the Columbia Icefield has been recognized as a 2015 winner of the prestigious Certificate of Excellence Award, placing it in the TripAdvisor Hall of Fame. Guests of the Glacier Adventure enjoy a unique journey by Ice Explorer on to the Athabasca Glacier for an up-close look and understanding of the Columbia Icefield’s iconic landmark.
The TripAdvisor reviews are in: the coolest attraction in the Canadian Rockies remains a hot favourite among visitors and guests from around the globe.
- The Glacier Adventure received the 2015 Certificate of Excellence based on consistently maintaining an overall rating of at least 90% from guest reviews around the world.
- After regularly ranking among the top experiences in Jasper National Park and achieving five successive wins of the annual Certificate of Excellence honour, the Glacier Adventure has attained an acclaimed spotlight in the TripAdvisor Hall of Fame.
TripAdvisor, Inc. operates as an online travel company. The company operates through two segments, Hotel and Other. Its travel research platform aggregates reviews and opinions about accommodations, destinations, activities and attractions, and restaurants that enable consumers to plan and book hotels, vacation rentals, flights, activities and attractions, and restaurants.
Finally, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), ended its last trade with -6.93% loss, and closed at $50.74.
Isis Pharmaceuticals, stated net income of $35.6 million and $18.9 million for the three and six months ended June 30, 2015, respectively, contrast to a net loss of $12.1 million and $43.4 million for the same periods in 2014. Isis’ significantly improved financial results were driven primarily by the more than $90 million of revenue Isis earned in the second quarter related to the upfront payment from Bayer to license ISIS-FXIRx. Isis raised its cash position during the first half of 2015, ending June with more than $750 million in cash contrast to about $730 million at December 31, 2014. The enhance in the Company’s cash position was primarily due to the more than $165 million in cash received from its partners in the first half of 2015.
“So far this year we have accomplished transactions that advance every element of our business. These transactions support our continued strong financial performance. However, their planned value now and in the future is even more important. Yesterday, we declared an expansion of our planned relationship with AstraZeneca that takes advantage of the breadth of our technology and provides us with a very strong partner to move forward with in the large and growing area of cardiometabolic and renal diseases. This planned collaboration, which is valued at up to more than $4 billion, will continue to expand our technology in the kidney and builds on our positive oncology and drug delivery collaborations. Early in the year, we initiated a new partnership with J&J that also enables us to expand the reach of our antisense technology. With J&J, we are focusing on the local treatment of inflammatory disease in the GI track, capitalizing on J&J’s expertise in this area. In May, we licensed ISIS-FXIRx to Bayer, a leader in the development and commercialization of antithrombotic drugs. Bayer plans to advance ISIS-FXIRx with a robust development plan designed to maximize the value of the drug. The completion of these unique collaborations since the starting of the year, each of which is already providing substantial added value to Isis, is an unparalleled achievement,” said B. Lynne Parshall, chief operating officer of Isis Pharmaceuticals. “Moreover, at the starting of the year, we created Akcea, a wholly owned partner, to develop and commercialize our suite of lipid drugs. The Akcea team is making excellent progress in building a high-quality team and preparing to commercialize volanesorsen. The importance of the Akcea portfolio of drugs to provide new treatments for patients with inadequately treated lipid disorders is reflected in the fact that this portfolio has been the subject of three articles in two major medical journals, The Lancet and The New England Journal of Medicine. This is a testament to the ability of antisense technology to approach targets that are not easily approachable with other therapeutic modalities and to rapidly identify potent and specific inhibitors to newly discovered targets that play key roles in disease.”
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
